Rumi Therapeutics Licenses New Fragile X Drug Candidate
The firm now holds rights to an IND-ready PDE2 inhibitor intended to address synaptic plasticity in patients.
Updated on Oct. 27, 2026 in Biotech
New York-based Rumi Therapeutics has secured a licensing agreement with Enthorin Therapeutics for RTX-7340, an investigational PDE2 inhibitor. The drug candidate is currently IND-ready, meaning the company has reached the stage required to submit an investigational new drug application to begin human trials for Fragile X syndrome.
Why it matters
This deal marks a strategic transition for Rumi Therapeutics from early-stage discovery to clinical development. By targeting PDE2 inhibition, the company aims to address the underlying synaptic dysfunction associated with neurodevelopmental conditions.
RTX-7340 functions as a phosphodiesterase-2 (PDE2) inhibitor, a class of enzymes that regulate intracellular signaling molecules. Studies show that pharmacological inhibition of PDE2 improves dendritic spine maturation, synaptic plasticity, and behavioral endpoints in animal models.
The players
Rumi Therapeutics
A New York-based biotechnology firm focused on neurodevelopmental research and the development of translational clinical programs.
Enthorin Therapeutics
A research entity that developed the PDE2 inhibitor candidate RTX-7340 now licensed to Rumi.
The details
The mechanism involves modulating synaptic plasticity—the ability of connections between neurons to strengthen or weaken over time—which is often impaired in Fragile X syndrome. Rumi Therapeutics plans to leverage these preclinical findings, which include corrected brain electrical activity, to design neurophysiological metrics for upcoming human studies. The research approach integrates data from human organoid studies—three-dimensional tissue cultures that mimic organ structures—to refine translational endpoints.
Timeline
October 27, 2026: Rumi Therapeutics announced the licensing deal for RTX-7340.
The Tech Race
This deal follows a broader trend of firms acquiring IND-ready assets to bolster the existing Fragile X syndrome clinical development pipeline. Rumi Therapeutics is now positioning itself to test whether PDE2 inhibition can successfully translate from mouse models to human neurophysiological efficacy.
RTX-7340 remains in the investigational stage and is not available for clinical use. Patients and families should monitor future filings with the FDA as Rumi Therapeutics transitions this candidate toward potential human clinical trials.
The takeaway
Rumi Therapeutics is moving to prove that PDE2 inhibition can improve social and cognitive endpoints in humans. Interested observers should watch for future disclosures regarding the submission of an investigational new drug application to the FDA.
Further reading
Explore the latest developments in medical innovation at the Biotech section.
Source note: This article includes information reported by Firstwordpharma.
